Hypothesis

The enteric nervous system (ENS) functions as an upstream master regulator that translates gut‑microbiome short‑chain fatty acid (SCFA) signals into systemic changes in epigenetic clock speed, autonomic tone, and inflammaging. Enhancing ENS integrity via targeted neuromodulation will amplify the age‑slowing effects of probiotic‑derived SCFAs, whereas ENS disruption will abolish these benefits.

Mechanistic Rationale

SCFAs—particularly butyrate—are known HDAC inhibitors that can increase acetylation of histones in ENS neurons, boosting cholinergic output and vagal afferent firing (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1339722/full). Heightened vagal activity suppresses NF‑κB signaling in microglia and peripheral macrophages, lowering circulating IL‑1β, TNF‑α, and IL‑6, thereby attenuating the inflammatory feed‑forward loop that drives epigenetic age acceleration (https://pmc.ncbi.nlm.nih.gov/articles/PMC9120705/). Simultaneously, ENS‑derived vasoactive intestinal peptide (VIP) and substance P reinforce tight‑junction integrity, reducing gut permeability and limiting translocation of microbial products that would otherwise trigger inflammaging. Thus, the ENS sits at the nexus where microbiome metabolites, autonomic output, and barrier function converge to set the pace of systemic aging.

Testable Predictions

1. Amplification: Combining a defined SCFA‑producing probiotic blend with transcutaneous vagus nerve stimulation (taVNS) will produce a greater reduction in epigenetic age (measured by Horvath’s clock) than either intervention alone.
2. Necessity: Chemogenetic inhibition of ENS cholinergic neurons in mice will block the epigenetic age‑slowing effect of SCFA supplementation, despite unchanged fecal SCFA levels.
3. Mediation: Improvements in heart‑rate variability (HRV) and decreased serum zonulin (a permeability marker) will mediate the relationship between ENS activation and epigenetic age deceleration.
4. Specificity: Alterations in DNA methylation will be enriched at promoters of inflammation‑related genes (e.g., Il6, Tnf) and stress‑response pathways, reflecting a shift from an inflammaging to a repair‑associated epigenotype.

Experimental Design

Human arm: A 12‑week, double‑blind, randomized, placebo‑controlled trial with four arms (placebo, probiotic only, taVNS only, probiotic+taVNS) in adults aged 60–80 with baseline HRV < 50 ms. Primary outcome: change in GrimAge epigenetic acceleration. Secondary outcomes: fecal SCFA concentrations (GC‑MS), HRV (time‑domain RMSSD), serum zonulin, IL‑6, TNF‑α, and cognitive composite scores. Animal arm: Colon‑targeted chemogenetic silencing of ChAT‑expressing ENS neurons in aged mice receiving either SCFA‑producing probiotic or vehicle. Epigenetic age measured via mouse blood Horvath‑clock analog; gut permeability assessed by FITC‑dextran flux; microglial activation quantified by Iba1 immunostaining.

Potential Outcomes and Falsifiability

If the probiotic+taVNS arm shows a statistically significant greater reduction in epigenetic age than monotherapies, and this effect correlates with HRV and permeability improvements, the hypothesis gains support. Conversely, if ENS inhibition does not diminish the probiotic’s epigenetic benefit, or if taVNS fails to augment SCFA effects, the ENS’s role as a master upstream controller would be refuted, indicating that observed correlations are parallel downstream phenomena rather than causal drivers.